384 related articles for article (PubMed ID: 30101644)
1. Apalutamide for the treatment of prostate cancer.
Rathkopf DE; Scher HI
Expert Rev Anticancer Ther; 2018 Sep; 18(9):823-836. PubMed ID: 30101644
[TBL] [Abstract][Full Text] [Related]
2. The development of apalutamide for the treatment of prostate cancer.
Isaacsson Velho P; Tofani Sant' Anna P; Pereira da Silva RF; Dal Ponte Ferreira R; Venero FC
Expert Opin Drug Discov; 2021 Mar; 16(3):217-226. PubMed ID: 33003959
[TBL] [Abstract][Full Text] [Related]
3. Apalutamide: A new agent in the management of prostate cancer.
May MB; Glode AE
J Oncol Pharm Pract; 2019 Dec; 25(8):1968-1978. PubMed ID: 31359832
[TBL] [Abstract][Full Text] [Related]
4. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
Halabi S; Jiang S; Terasawa E; Garcia-Horton V; Ayyagari R; Waldeck AR; Shore N
J Urol; 2021 Aug; 206(2):298-307. PubMed ID: 33818140
[TBL] [Abstract][Full Text] [Related]
5. The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels.
Werutsky G; Maluf FC; Cronemberger EH; Carrera Souza V; Dos Santos Martins SP; Peixoto F; Smaletz O; Schutz F; Herchenhorn D; Santos T; Mavignier Carcano F; Queiroz Muniz D; Nunes Filho PRS; Zaffaroni F; Barrios C; Fay A
BMC Cancer; 2019 May; 19(1):487. PubMed ID: 31122212
[TBL] [Abstract][Full Text] [Related]
6. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
Saad F; Cella D; Basch E; Hadaschik BA; Mainwaring PN; Oudard S; Graff JN; McQuarrie K; Li S; Hudgens S; Lawson J; Lopez-Gitlitz A; Yu MK; Smith MR; Small EJ
Lancet Oncol; 2018 Oct; 19(10):1404-1416. PubMed ID: 30213449
[TBL] [Abstract][Full Text] [Related]
7. Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer.
Dellis AE; Papatsoris AG
Expert Opin Investig Drugs; 2018 Jun; 27(6):553-559. PubMed ID: 29856649
[TBL] [Abstract][Full Text] [Related]
8. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Ladouceur M; Behl AS; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
Adv Ther; 2020 Jan; 37(1):501-511. PubMed ID: 31813086
[TBL] [Abstract][Full Text] [Related]
9. Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.
Al-Salama ZT
Drugs; 2019 Sep; 79(14):1591-1598. PubMed ID: 31489589
[TBL] [Abstract][Full Text] [Related]
10. Apalutamide: A Review in Metastatic Castration-Sensitive Prostate Cancer.
Hoy SM
Drugs; 2020 Oct; 80(15):1579-1585. PubMed ID: 32930958
[TBL] [Abstract][Full Text] [Related]
11. Darolutamide in hormone-sensitive and castration-resistant prostate cancer.
Palmieri VE; Roviello G; D'Angelo A; Casadei C; De Giorgi U; Giorgione R
Expert Rev Clin Pharmacol; 2021 May; 14(5):535-544. PubMed ID: 33685318
[No Abstract] [Full Text] [Related]
12. Apalutamide for the treatment of patients with castration-resistant prostate cancer.
Hauke R
Drugs Today (Barc); 2018 Oct; 54(10):585-590. PubMed ID: 30398479
[TBL] [Abstract][Full Text] [Related]
13. Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer.
Zhao J; Ning S; Lou W; Yang JC; Armstrong CM; Lombard AP; D'Abronzo LS; Evans CP; Gao AC; Liu C
Mol Cancer Ther; 2020 Aug; 19(8):1708-1718. PubMed ID: 32430485
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety Exposure-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer.
Perez-Ruixo C; Ackaert O; Ouellet D; Chien C; Uemura H; Olmos D; Mainwaring P; Lee JY; Yu MK; Perez-Ruixo JJ; Smith MR; Small EJ
Clin Cancer Res; 2020 Sep; 26(17):4460-4467. PubMed ID: 32561663
[TBL] [Abstract][Full Text] [Related]
15. Drug-drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors.
Appukkuttan S; Ko G; Fu C; Bannister B; Kong SX; Jhaveri J; Freedland SJ
Expert Rev Anticancer Ther; 2024 May; 24(5):325-333. PubMed ID: 38469875
[TBL] [Abstract][Full Text] [Related]
16. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
Smith MR; Saad F; Chowdhury S; Oudard S; Hadaschik BA; Graff JN; Olmos D; Mainwaring PN; Lee JY; Uemura H; Lopez-Gitlitz A; Trudel GC; Espina BM; Shu Y; Park YC; Rackoff WR; Yu MK; Small EJ;
N Engl J Med; 2018 Apr; 378(15):1408-1418. PubMed ID: 29420164
[TBL] [Abstract][Full Text] [Related]
17. Prospects of Treating Prostate Cancer through Apalutamide: A Mini-Review.
Singh R; Alsayadi YMMA; Singh VJ; Chawla PA; Rawal RK
Anticancer Agents Med Chem; 2022; 22(6):1056-1067. PubMed ID: 34431470
[TBL] [Abstract][Full Text] [Related]
18. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer.
Small EJ; Saad F; Chowdhury S; Oudard S; Hadaschik BA; Graff JN; Olmos D; Mainwaring PN; Lee JY; Uemura H; De Porre P; Smith AA; Zhang K; Lopez-Gitlitz A; Smith MR
Ann Oncol; 2019 Nov; 30(11):1813-1820. PubMed ID: 31560066
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of apalutamide for the treatment of prostate cancer.
Boukovala M; Spetsieris N; Efstathiou E
Expert Opin Pharmacother; 2020 Sep; 21(13):1537-1546. PubMed ID: 32543237
[TBL] [Abstract][Full Text] [Related]
20. An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer.
Tsuchiya T; Imanaka K; Iwaki Y; Oyama R; Hashine K; Yamaguchi A; Uemura H
Int J Clin Oncol; 2019 Dec; 24(12):1596-1604. PubMed ID: 31446511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
